Contact Us
Drug Search Results
More Filters [+]

Propagermanium

Alternative Names: propagermanium, dmx-200, dmx200, dmx 200
Latest Update: 2024-12-19
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: CCR2 Inhibitor,ARB Blocker

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Dimerix Bioscience
Company Location: NEW YORK NY 10005
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Propagermanium

Countries in Clinic: Argentina, Australia, Brazil, Denmark, France, Germany, Hong Kong, Italy, New Zealand, Portugal, Spain, Taiwan, United Kingdom, United States

Active Clinical Trial Count: 5

Highest Development Phases

Phase 3: Glomerulosclerosis, Focal Segmental|Kidney Diseases

Phase 1: Proteinuria

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
DMX-200-301

P3

Unknown Status

Glomerulosclerosis, Focal Segmental

2026-11-30

ACTION3

P3

Active, not recruiting

Glomerulosclerosis, Focal Segmental

2026-08-08

ACTION3

P3

Recruiting

Kidney Diseases|Glomerulosclerosis, Focal Segmental

2024-06-28

ACTION3

P3

Recruiting

Glomerulosclerosis, Focal Segmental

2024-06-01

47%

Recent News Events

Date

Type

Title

11/01/2024

News Article

 Critical Gaps in FSGS Treatment Highlight Need for New Therapies, with Pipeline Assets from Travere, Vertex, and Dimerix Poised to Address Unmet Needs

05/04/2024

PubMed

 Investigation of Strategies to Block Downstream Effectors of AT1R-Mediated Signalling to Prevent Aneurysm Formation in Marfan Syndrome.

10/04/2023

News Article

 Focal Segmental Glomerulosclerosis Pipeline, Clinical Trials Assessment, and NDA Approvals 2023 (Updated)

04/11/2023

PubMed

 Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support-Free Days in Patients Hospitalized With COVID-19: A Randomized Clinical Trial.

04/01/2023

PubMed

 GM-CSF-producing CCR2+ CCR6+ Th17 cells are pathogenic in dextran sodium sulfate-induced colitis model in mice.

09/21/2022

News Article

 Despite Amplified Use of SGLT2 Inhibitors for Glomerular Diseases, EU and US Nephrologists Express a Continued Strong Desire for New Treatment Options for FSGS Patients, Spherix Reports

07/29/2020

News Article

 DIMERIX's DMX-200 Posts Strong Results in Kidney Disease Trial

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions